BTK Inhibitors and Chemoimmunotherapy for CLL
نویسندگان
چکیده
منابع مشابه
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.
Optimal management of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) is dictated by patient characteristics, prior therapy, and response to prior therapy. We report the final analysis of combined fludarabine, cyclophosphamide, and rituximab (FCR) for previously treated patients with CLL and identify patients who benefit most from this therapy. We explore efficacy of FCR in...
متن کاملPerspectives Risk categories and refractory CLL in the era of chemoimmunotherapy
1Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany; 2Department of Medicine V, University of Heidelberg, Heidelberg, Germany; 3Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; 4Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn...
متن کاملIbrutinib and novel BTK inhibitors in clinical development
Small molecule inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clinical outcomes in cancer patients. Recently Bruton's tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune di...
متن کاملReview Series CHRONIC LYMPHOCYTIC LEUKEMIA: TAKING A BIG LEAP FORWARD Initial treatment of CLL: integrating biology and functional status
Chemoimmunotherapy (CIT) has been the standard first-line treatment of patients with chronic lymphocytic leukemia (CLL). In the last several years, major strides have been made in understanding the biology of CLL, and fortunately, several of these discoveries are making their way into the clinics. These include novel CD20 monoclonal antibodies (mAb) (ofatumumab and obinutuzumab), Bruton tyrosin...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
Optimal management of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) is dictated by patient characteristics, prior therapy, and response to prior therapy. We report the final analysis of combined fludarabine, cyclophosphamide, and rituximab (FCR) for previously treated patients with CLL and identify patients who benefit most from this therapy. We explore efficacy of FCR in...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Lymphoma Myeloma and Leukemia
سال: 2020
ISSN: 2152-2650
DOI: 10.1016/s2152-2650(20)30449-3